Home Healthcare IT Global Stomach Cancer Market Size, Top Share, Report to 2032

Stomach Cancer Market

Stomach Cancer Market Size, Share & Trends Analysis Report By Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), By Therapy Type (Chemotherapy , Targeted Therapy , Immunotherapy , Radiation Therapy , Surgery ), By End-User (Ambulatory Surgery Centers , Hospitals and Specialty Clinics , Other End-Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI327DR
Study Period 2020-2032 CAGR 13.3%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD 3.61 billion
Forecast Year 2032 Forecast Year Market Size USD 11.10 billion
Largest Market North America Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global stomach cancer market size was valued at USD 3.61 billion in 2023. It is estimated to reach USD 11.10 billion by 2032, growing at a CAGR of 13.3% during the forecast period (2024–2032). The global stomach cancer market is primarily driven by the growing patient pool suffering from this disease. There has also been a rise in awareness initiatives aiming to educate people about stomach cancer, risk factors, symptoms, and the importance of early detection, which is anticipated to augment the market expansion. Moreover, in recent times, there has been an increase in research and clinical trials focusing on stomach cancer, resulting in the advancement of treatment options and prevention strategies, which is expected to create market expansion opportunities.


  • Adenocarcinoma dominates the type segment
  • Chemotherapy dominates the therapy type segment 
  • North America is the highest shareholder in the global market

Market Overview

Stomach cancer, known as gastric cancer, is a type of cancer that begins in the lining of the stomach. It usually develops slowly over many years. The exact cause of stomach cancer is not known, but several factors may increase the risk of developing it, including helicobacter pylori infection, dietary factors, smoking, family history, and age and gender, amongst others.

Stomach cancer symptoms can include nausea, vomiting, unintended weight loss, difficulty swallowing, blood in the stool or vomit, fatigue, and ongoing abdominal pain or discomfort. Laboratory testing, biopsies, and imaging tests (like CT scans or endoscopies) are frequently used in diagnosis. Depending on the cancer's stage, location, and overall health of the patient, treatment options for stomach cancer may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Market Dynamics

Global Stomach Cancer Market Drivers

Rising Incidence of Stomach Cancer

The market for stomach cancer is significantly influenced by the rising incidence of the disease, which in turn stimulates demand for a wide range of medical interventions and treatments. The number of diagnosed cases increases with the demand for specialized diagnostic tools, therapies, medications, and surgical procedures to combat the disease. Due to this increased demand, pharmaceutical companies are driven to grow the market through research and development endeavors to develop novel treatments and enhance pre-existing ones.

As per the GLOBOCAN 2020 estimates, stomach cancer accounted for around 800,000 fatalities, representing 7.7% of the total cancer-related fatalities. Among both genders, it ranked as the fourth most prevalent cause of cancer-related deaths. In 2020, there were approximately 1.1 million newly diagnosed cases of stomach cancer, which accounted for 5.6% of all cancer cases. The National Cancer Institute has projected that the incidence of newly diagnosed stomach cancer will peak at 26,500 cases in 2023. Therefore, the expected increased occurrence of stomach cancer will stimulate growth in the global market.

Growing Awareness

Awareness programs play a critical role in the stomach cancer market by spreading awareness to the general public regarding risk factors, symptoms, and the criticality of early detection. These initiatives encourage individuals to undergo screening procedures such as endoscopy, genetic testing, and imaging examinations by increasing public awareness. These programs enhance patient outcomes by facilitating the detection of stomach cancer during its early, more treatable phases through the promotion of routine screenings.

For instance, the Stomach Cancer Foundation of Canada promotes global consciousness through its annual initiative, "The Power of Periwinkle," which takes place on November 30. This day, over 120 landmarks across Europe, Asia, the United States, Canada, and Australia are illuminated in periwinkle blue, the symbolic color associated with stomach cancer awareness.

Likewise, Healio reviews recent news and research on stomach cancer in observance of Stomach Cancer Awareness Month. This includes new information that supports the cost-effectiveness of laparoscopic gastrectomy, the effectiveness of pembrolizumab, and a novel marker that identifies distant metastases and poor prognoses of survival. This will accelerate the expansion of the world market.

Global Stomach Cancer Market Restraint

Side Effects of Treatment 

The side effects of treatment for stomach cancer can significantly impact patient well-being and treatment adherence, thereby restraining market growth. Chemotherapy, a cornerstone of stomach cancer treatment, often induces adverse effects such as nausea, vomiting, fatigue, and hair loss, which can diminish patients' quality of life and lead to treatment interruptions or dose reductions.

Similarly, radiation therapy may cause gastrointestinal symptoms, fatigue, and skin irritation, further complicating patients' experiences. These side effects not only contribute to physical discomfort but also psychological distress, potentially deterring patients from seeking or continuing treatment. Managing these side effects requires supportive care interventions and medications, adding to treatment's overall cost and complexity.

Global Stomach Cancer Market Opportunities

Growing Research and Development

In recent years, there has been a rise in the research and clinical trials related to stomach cancer, which has led to the development of better treatment options and preventive measures. For instance, in August 2023, an international phase 3 clinical trial conducted in collaboration with Weill Cornell Medicine and NewYork-Presbyterian demonstrated that the new targeted treatment zolbetuximab, when combined with standard chemotherapy, improved the survival rate of patients with advanced gastric or gastroesophageal junction cancer that exhibited high levels of a specific biomarker.

Furthermore, a study by researchers at Duke University School of Medicine in October 2023 analyzed health data from more than 80,000 adults in the Southern region. The results of the study showed that those who took supplements, particularly Black adults, had a 30% lower risk of stomach cancer than those who did not. The study's findings need to be confirmed by additional research because they are preliminary. This demands more research and development in the field, thereby creating opportunities for market growth opportunities.

Regional Analysis

Based on region, the global stomach cancer market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global stomach cancer market shareholder and is expected to expand substantially during the forecast period. The North American stomach cancer market is expanding due to the increasing number of specialty clinics and hospitals offering cancer treatment, the availability of advanced technologies, and the incidence of stomach cancer. The International Agency for Research on Cancer reports that 29,275 new cases of stomach cancer were identified in 2018, with 1,404 deaths attributed to the disease. As per the Canadian Cancer Society, in 2017, 2100 Canadians succumbed to stomach cancer, of the 3500 cases of stomach cancer diagnosed in the country alone. Likewise, according to the American Cancer Society, more than 26,000 Americans will be diagnosed with stomach cancer in 2024, and nearly 11,000 will succumb to the disease. Annually, approximately 1.5% of newly diagnosed cancers in the United States are stomach cancers.

Compared to numerous other malignancies, stomach cancer has received considerably less attention in the United States. However, a group of physician-scientists hailing from Stanford, with the backing of the National Cancer Institute (NCI), endeavors to alter the current status paradigm. Principal Investigators Joo Ha Hwang, MD, Ph.D., and Hanlee Ji, MD, who are members of a multidisciplinary team investigating "Precision Interception of Gastric Cancer Precursors Through Molecular and Cellular Risk Stratification," were granted USD 9.15 million by the NCI in September 2023. The National Institutes of Health has awarded only two program project grants to investigate gastric cancer. As a result, all of these factors accelerate the expansion of the regional market.

Asia-Pacific accounts for a considerable share of the stomach cancer market, primarily due to a high incidence rate in countries such as Japan, Korea, and China. Asia is reported to account for approximately 75% of all newly diagnosed cases and fatalities of stomach cancer, according to GLOBOCAN 2020 estimates. Moreover, the regional market leaders are engaged in developing innovative therapeutics to combat stomach cancer. For instance, CARsgen Therapeutics, a Chinese biotechnology company, has initiated a Phase II clinical trial of CT041 in the United States.

Moreover, the trial is currently recruiting patients who have advanced gastric cancer or gastroesophageal junction cancer (GC/GEJ) and are positive for Claudin18.2 (CLDN18.2). The autologous chimeric antigen receptor (CAR) T-cell product candidate CT041 targets the CLDN18.2 protein with its mechanism of action. CT041 will be evaluated in the trial as a treatment option for patients with advanced GC/GEJ who are CLDN18.2-positive and have not responded positively to two or more prior systemic regimens. These factors contribute to the expansion of the regional market.

Report Scope

Report Metric Details
By Type
  1. Adenocarcinoma
  2. Lymphoma
  3. Gastrointestinal Stromal Tumor
  4. Carcinoid Tumor
  5. Others
By Therapy Type
  1. Chemotherapy 
  2. Targeted Therapy 
  3. Immunotherapy 
  4. Radiation Therapy 
  5. Surgery 
By End-User
  1. Ambulatory Surgery Centers 
  2. Hospitals and Specialty Clinics 
  3. Other End-Users
Company Profiles Merck & Co. Inc. GlaxoSmithKline plc CareFusion Apotex Inc. Sanofi Takeda Pharmaceutical Company Limited Pfizer Inc. Eli Lilly and Company Dr. Reddy’s Laboratories Ltd.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global stomach cancer market is bifurcated into type, therapy type, and end-users.

Based on type, the global stomach cancer market is segmented into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. 

The adenocarcinoma segment is anticipated to capture the largest market share. Adenocarcinoma is an organ-specific malignancy that develops from the glandular cells. The function of glandular cells varies by organ but includes the production and secretion of fluids such as enzymes, hormones, and mucus. The precise indications and options for treatment for adenocarcinoma are dependent upon the cancer's site and stage. Moreover, surgical intervention, chemotherapy, radiation therapy, targeted therapy, immunotherapy, or a combination of these methods may be utilized during treatment. Adequate treatment and timely detection are essential components in enhancing prognoses for patients afflicted with adenocarcinoma.

Furthermore, numerous drugs are undergoing development to create an innovative remedy for adenocarcinoma. An example of this is the phase 2 DisTinGuish study, which aims to evaluate the effectiveness of a combination of tislelizumab, DKN-01, and chemotherapy as the primary therapeutic approach for patients diagnosed with advanced gastroesophageal adenocarcinoma in January 2024. These factors stimulate market expansion.

Based on therapy type, the global stomach cancer market is segmented into targeted therapy, chemotherapy, radiation therapy, immunotherapy, and surgery. 

The chemotherapy segment is anticipated to own the market share. Chemotherapy is a form of cancer treatment in which medications are utilized to destroy tumor cells. These medications are effective by targeting cells that divide quickly, which is characteristic of cancer cells. Chemotherapy can be delivered via oral route (pills or beverages) or intramuscularly (vein or muscle injection). The medicines can reach cancer cells throughout the body by traveling through the bloodstream.

Chemotherapy is frequently utilized to treat stomach cancer. Chemotherapy medications frequently employed in managing stomach cancer are capecitabine, docetaxel, paclitaxel, fluorouracil (5-FU), cisplatin, oxaliplatin, and capecitabine. The optimal combination or monotherapy of these medications is contingent upon the malignancy's particular attributes and the patient's overall well-being.

Based on end-users, the global stomach cancer market is bifurcated into ambulatory surgery centers, hospitals and specialty clinics, and others.

Patients diagnosed with stomach cancer are given medical care by a multidisciplinary team comprising oncologists, surgeons, radiologists, nurses, dietitians, and social workers in hospitals and specialty clinics. Each patient's customized treatment plan may include some or all of the aforementioned modalities. Patients are often provided with nutritional support, pain management, and counseling services to help them manage the psychological and physical aspects of cancer treatment.

Market Size By Type

Market Size By Type
  • Adenocarcinoma
  • Lymphoma
  • Gastrointestinal Stromal Tumor
  • Carcinoid Tumor
  • Others
  • Recent Developments

    • October 2023- Phanes, in partnership with Keytruda manufacturer Merck, entered into a supply agreement and clinical trial collaboration. Currently, patients are enrolled in a phase 1 clinical trial to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of PT886 in patients diagnosed with locally advanced or metastatic gastric, GEJ, or pancreatic cancer.
    • November 2023- The FDA approved Merck's Keytruda in combination with chemotherapy as the first treatment for adult patients with gastric cancer.

    Key Players

    Stomach Cancer Market Share of Key Players

    Stomach Cancer Market Share of Key Players
    Merck & Co. Inc. GlaxoSmithKline plc CareFusion Apotex Inc. Sanofi Takeda Pharmaceutical Company Limited Pfizer Inc. Eli Lilly and Company Dr. Reddy’s Laboratories Ltd. Others

    Frequently Asked Questions (FAQs)

    How big is the stomach cancer market?
    The global stomach cancer market size was valued at USD 3.61 billion in 2023. It is estimated to reach USD 11.10 billion by 2032, growing at a CAGR of 13.3% during the forecast period (2024–2032).
    Asia Pacific region has the highest growth rate in the stomach cancer market.
    Increasing incidence of stomach cancer, growing awareness are the major growth factors of the stomach cancer market.
    Adenocarcinoma segment is the leading segment for the market during forecast period.
    The key players in the global stomach cancer market include Merck & Co. Inc., GlaxoSmithKline plc, CareFusion, Apotex Inc., Sanofi, Takeda Pharmaceutical Company Limited, Pfizer Inc., Eli Lilly and Company, Dr. Reddy’s Laboratories Ltd.

    We are featured on :